Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | IL1B | P01584 | 7/20 | 0.38 |
| ▸ | RBP4 | P02753 | 11/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23933508 | 1.00 | GRIN2B (0.39) | GRIN2BIL1BRBP4CYP3A4CYP2C9 | |
| SCHEMBL23933511 | 1.00 | GRIN2B (0.39) | GRIN2BIL1BRBP4CYP3A4CYP2C9 | |
| SCHEMBL25625907 | 0.85 | NR1H2 (0.41) | GRIN2BIL1BJAK2JAK1 | |
| SCHEMBL30455542 | 0.85 | NR1H2 (0.41) | GRIN2BIL1BJAK2JAK1 | |
| SCHEMBL23956997 | 0.85 | NR1H2 (0.41) | GRIN2BIL1BJAK2JAK1 | |
| SCHEMBL29270325 | 0.82 | IL1B (0.49) | IL1BNLRP3 | |
| SCHEMBL30665802 | 0.82 | IL1B (0.49) | IL1BNLRP3 | |
| SCHEMBL23499460 | 0.81 | CNR2 (0.34) | JAK2JAK1 | |
| SCHEMBL23933599 | 0.79 | GRIN2B (0.39) | GRIN2BIL1BRBP4CYP3A4CYP2C9 | |
| SCHEMBL23933595 | 0.79 | GRIN2B (0.39) | GRIN2BIL1BRBP4CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| EP-4139303-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021216951-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | GRIN2B 151/4885IL1B 4584/4885RBP4 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.